Filing Flows › Tonix Pharmaceuticals Holding (TNXP) › Tosymra revenue
Tonix Pharmaceuticals Holding (TNXP) Tosymra revenue by quarter
Tonix Pharmaceuticals Holding's Tosymra revenue was $594K in Q2 2026 (second quarter 2026), +174% from Q1 2026. Over the last 6 quarters it ranged from $95K (Q4 2024) to $708K (Q3 2025).
| Quarter | Tosymra revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $594K | +174% | +39% |
| Q1 2026 | $217K | -69% | -46% |
| Q3 2025 | $708K | +65% | — |
| Q2 2025 | $428K | +6% | — |
| Q1 2025 | $403K | +324% | — |
| Q4 2024 | $95K | — | — |
Q2 2026 at a glance
Tonix Pharmaceuticals Holding, Q2 2026: revenue $13.5M (+578% year over year), operating margin -314.1%, net loss $40.6M, operating cash flow −$42.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Tonix Pharmaceuticals Holding's Tosymra revenue?
Tonix Pharmaceuticals Holding's Tosymra revenue was $594K in Q2 2026 (second quarter 2026), +174% from Q1 2026.
How has Tonix Pharmaceuticals Holding's Tosymra revenue changed?
Over the last 6 quarters it ranged from $95K (Q4 2024) to $708K (Q3 2025).
Q2 2026 results → · How Tonix Pharmaceuticals Holding makes money →